Ophthalmology / Solid tumors

Mechanism of action / Target

PMC-403 is a monoclonal antibody that targets the human TIE2 that regulate the angiogenesis and vessel maturation in endothelial cells. It binds to TIE2 expressing endothelial cells and normalize VEGF-induced pathological leaky blood vessels in eyes and TME (tumor microenvironment).


PMC-403 was tested in various vessel-related diseases, such as AMD (Age-related Macular Degeneration), DR (Diabetic Retinopathy), and even solid tumors. In these models, significant vessel normalizing effects were found which suggest versatile use in a wide range of indications. PharmAbcine initiated the GLP-tox study of PMC-403 in 2Q21 and expects an IND filing for eye diseases in 3Q22.


* The nonclinical data of PMC-403 in oncology at AACR 2022

* The nonclinical data of PMC-403 in ophthalmology at ARVO 2021

* EMM / 2023 / An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone

     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea

     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 

     COPYRIGHT BY PharmAbcine Inc.